Trial Profile
Effect of roflumilast on exacerbation rate in patients with COPD. The HERMES Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms HERMES
- Sponsors Takeda
- 11 Sep 2013 Pooled analysis presented at the 23rd Annual Congress of the European Respiratory Society.
- 07 May 2012 Company added in the association field as reported by ClinicalTrials.gov.
- 28 Sep 2011 Pooled analysis assessing rate and duration of exacerbations as well as the overal steroid load presented at the 21st Annual Congress of the European Respiratory Society.